updat model thought reflect detail confer
call occur march confer subsequ develop take
opportun increas price target
report result issu detail guidanc march
healthcar confer unabl updat forecast time
take opportun updat forecast price target reflect detail provid
time call subsequ event
similar last year forecast revenu gener
first quarter full year cadenc also similar past year
forecast revenu growth moder y/i revenu forecast
line consensu forecast overal test report volum
growth y/i nipt y/i carrier test y/i feel
bia potenti slightli upsid offset volum growth expect asp
declin y/i q/q asp declin larg function new carrier
test code carri forward nipt trend fewer catch payment
posit moldx decis posit surpris transplant diagnost
link note manag describ pre-submiss interact moldx
encourag contrari prior understand manag indic
subsequ submiss requir ntra local noridian parti moldx
program plausibl could start reimburs ntra transplant product
earli septemb current associ revenu contribut contempl
guidanc forecast registri studi initi on-going track
ip lawsuit cover file intellectu properti infring
claim done deep dive given ip transplant
seemingli similar use part cfdna ip use ntra core chemistri
includ nipt given familiar exist ip landscap
includ stanford/nolan lab believ high level like
sever sourc potenti revenu upsid year earlier expect
transplant revenu see acog guidelin expans average-risk nipt
fulli reflect models/guid note guidanc model
includ bgi/signatera revenu
increas price target equat price/sal
multipl line current peer group multipl
pleas see page report import disclosur
nipt market current estim opportun potenti
expand measur volum nipt becom well adopt averag
risk segment well posit capit opportun believ
current lead us nipt provid compani larg sale forc target
us averag risk market also abl leverag nipt sale forc
crosssel opportun product reproduct medicin addit
cloud-bas bioinformat platform provid global reach enabl
compani effici achiev scale compani grow long-term strategi also
attract sinc core technolog could posit compani well potenti
massiv base case
cross sell rate panorama
product line expect
averag risk nipt guidelin inclus
reimburs occur sooner
cross sell rate product higher
anticip
reimburs occur later
clinic valid microdelet
establish payment remain low
success constel sale allow
scale improv margin
price eros continu nipt
high risk growth moder
genet test diagnost compani develop
commerci non-invas method analyz dna use massiv multiplex
pcr mmpcr approach predict algorithm compani offer proprietari genet
test servic reproduct medicin concept natera product includ
panorama non-invas prenat screen test nipt horizon carrier screen
inherit diseas test field reproduct genet compani offer
major test clia lab also offer cloud-bas softwar call
constel allow global laboratori access bioinformat platform
futur compani plan launch sever liquid biopsi test use mmpcr
technolog cancer diagnost
compani report cowen compani
cagrcommentstot revenu revenu guid panorama horizon genet test includ vistara transplant pg includ transplant revenu guidancelicens includ evercord signatera contract annual growth panorama horizon genet test includ vistara transplant pg includ evercord test report access test constel test test panorama nipt constel nipt hc test vistara transplant dx poc pg test pat test growth access test constel test test panorama nipt constel nipt hc test vistara transplant dx poc pg test pat test cowen
compani report thomson eikon cowen compani
revenu guid access long term target cog reiter gross target develop expens sg expens oper income/expens interest debt facil libor drawn due oper comp oper net incom count mm gross oper consensu estim cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit custom adopt could slower expect
averag risk non-invas prenat test reimburs clinic guidelin hurdl
intens competit expect lead greater expect share loss
price eros less expect contribut non-panorama product
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank
servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc april et dissemin april et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
